Drug resistance in solid tumors remains a major obstacle in oncology, frequently leading to treatment failure and disease relapse. A central contributor to ...

This will help advance the field of organoid-based cancer models." The review on tissue dissociation techniques is poised to ...

Researchers are engineering immune cells to take aim at solid tumors. Over the past few years, the treatment of some hard-to-treat blood cancers has been revolutionized by therapies based on ...

But malignancies that involve solid tumors have proved far more challenging for these new technologies. As yet, there has been no engineered cell therapy for solid tumors, which make up the ...

Among patients with solid tumors, 26% of those with CHIP had TI-CH. TI-CH conferred a risk of death from any cause that was 1.17 times (95% CI, 1.06 to 1.29) as high as the risk with CHIP in the ...

One of these was looking at a protein-coding gene called methionine adenosyltransferase 2a (MAT2A) in patients with solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. These ...

“This has been demonstrated in the hematological cancer space and Tecelra’s approval is a significant milestone in our journey to expand cell therapy to solid tumors.” Like CAR T ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an immunotherapy trial offered stunning results. By Gina Kolata When a person ...